Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti-Vascular Endothelial Growth Factor Agents for Wet Age-Related Macular Degeneration

Continuous fixed-interval dosing of anti-VEGF therapy in patients with exudative AMD results in favorable long-term preservation out to 7 years, with vision stabilizing or improving in 93.2% of eyes. Additionally, 43.2% of patients maintained driving vision in the treatment eye at 7 years compared with 10.1% at baseline. Our data suggest better outcomes with continuous therapy over published results with sporadic, as-needed therapy.